The Anti Vegf Market segment is highly diversified, categorized by disease, drug class, and route of administration. Based on disease, the market is segmented into age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and other ophthalmic conditions. AMD currently holds the largest share due to its high prevalence in the aging population. However, the DME segment is poised for rapid growth, driven by the global diabetes epidemic.

By drug class, the market is primarily divided into monoclonal antibodies and fusion proteins, with key products like Eylea and Lucentis leading the charge. The emergence of biosimilars is creating a new segment that is expected to grow rapidly. Furthermore, the market can be segmented by route of administration, with intravitreal injections being the most common. New innovations in sustained-release delivery systems are expected to create a new, high-growth sub-segment.